GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Cash-to-Debt

Notable Labs (Notable Labs) Cash-to-Debt : 5.77 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Notable Labs's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.77.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Notable Labs could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Notable Labs's Cash-to-Debt or its related term are showing as below:

NTBL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.78   Med: 4.38   Max: 5.77
Current: 5.77

During the past 3 years, Notable Labs's highest Cash to Debt Ratio was 5.77. The lowest was 1.78. And the median was 4.38.

NTBL's Cash-to-Debt is ranked worse than
52.11% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs NTBL: 5.77

Notable Labs Cash-to-Debt Historical Data

The historical data trend for Notable Labs's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Notable Labs Cash-to-Debt Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Cash-to-Debt
1.78 4.38 5.77

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
Cash-to-Debt 1.78 4.38 5.77

Competitive Comparison of Notable Labs's Cash-to-Debt

For the Biotechnology subindustry, Notable Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Notable Labs's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Notable Labs's Cash-to-Debt falls into.


Notable Labs Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Notable Labs's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=11.825 / (0.523 + 1.526)
=5.77

Notable Labs's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=11.825 / (0.523 + 1.526)
=5.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs  (NAS:NTBL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Notable Labs Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Notable Labs's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Notable Labs (Notable Labs) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Cash-to-Debt
Comparable Companies
NLSP ACST AGE CRBP NBIO CLRB AIM PLUR BIXT SNSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Website
https://notablelabs.com
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.